Menogon75 IU

Menogon is a preparation of human menopausal gonadotropin (hMG), containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is indicated for:

• Established/approved use in women: Treatment of anovulatory infertility in women who have not responded to clomiphene citrate therapy, to induce ovulation.
• Established/approved use in women (ART): Controlled ovarian stimulation (superovulation) as part of an assisted reproductive technology (ART) program such as in-vitro fertilization (IVF), in conjunction with human chorionic gonadotropin (hCG).
• Established/approved use in men (adjunct therapy): Treatment of male infertility due to hypogonadotropic hypogonadism, used in combination with hCG to stimulate spermatogenesis; Menogon alone is not effective in men without prior/concurrent hCG therapy.

Menogon is not effective in patients with primary ovarian or testicular failure, since it requires a responsive gonad.

Each vial of Menotrophin contains purified or highly purified human menopausal gonadotropin, standardized to provide a fixed ratio of FSH activity and LH activity (commonly 75 IU FSH + 75 IU LH per vial, though strengths vary by brand). It is supplied as a lyophilized (freeze-dried) powder for injection, together with a diluent (sterile solvent) for reconstitution.

Menogon is a gonadotropin preparation extracted and purified from the urine of postmenopausal women. It supplies both FSH and LH bioactivity, which are the natural pituitary hormones responsible for stimulating follicular development and ovulation in women, and spermatogenesis in men. Menogon is administered by injection under specialist (fertility clinic) supervision as part of a monitored ovulation-induction or controlled ovarian stimulation protocol, or for male infertility related to gonadotropin deficiency.

Menogon belongs to the therapeutic class of gonadotropins, specifically human menopausal gonadotropin (hMG) preparations used as ovulation-inducing and fertility-stimulating agents.

Menotrophin supplies exogenous FSH and LH activity that mimics the natural pituitary gonadotropins.

• In women: The FSH component stimulates growth and maturation of ovarian follicles; the LH component supports theca cell androgen/estrogen production and, together with a subsequent hCG trigger, supports final oocyte maturation and ovulation.
• In men: The FSH component stimulates Sertoli cells to support spermatogenesis, while concurrent hCG (with LH-like activity) stimulates Leydig cell testosterone production, which is necessary for sperm production in men with hypogonadotropic hypogonadism.

Onset of a measurable ovarian or testicular response typically takes days to weeks of repeated dosing, with response monitored by ultrasound and serum hormone (estradiol/testosterone) measurements.

Menogon is given by subcutaneous (SC) or intramuscular (IM) injection only, after reconstitution with the supplied diluent immediately before use. It is not for oral, intravenous, or intravaginal use. Injection technique and site should be as instructed by the prescribing clinic; many patients or caregivers are trained to self-administer SC injections at home under medical guidance, while some formulations/protocols require IM administration by a healthcare professional.

Formal drug-interaction studies with Menogon are limited, as it is a protein hormone given by injection with minimal systemic drug-metabolizing enzyme involvement. Clinically relevant points:

• Clomiphene citrate: Often used together with Menogon in combined ovulation-induction protocols; this is an intentional combination therapy rather than an adverse interaction, but it increases the risk of multiple follicular development.
• Other fertility medications (hCG, GnRH agonists/antagonists): Used concurrently as part of standard ART protocols under specialist supervision; concurrent use requires careful monitoring to reduce the risk of ovarian hyperstimulation syndrome (OHSS) (see Precautions and Warnings).

No significant interactions with common oral medications (e.g., antibiotics, analgesics) are established; inform the treating physician of all medications being used.

Common and important adverse effects reported with Menogon include:

• Injection site reactions: pain, redness, bruising, or swelling
• Mild ovarian enlargement and pelvic discomfort/bloating
• Headache, mood changes, fatigue
• Nausea
• Breast tenderness
• Ovarian hyperstimulation syndrome (OHSS), ranging from mild to severe (see Precautions and Warnings for details)
• Multiple pregnancy (twins or higher-order) as a consequence of the intended pharmacologic effect
• Rarely, thromboembolic events, ovarian torsion, or hypersensitivity/allergic reactions

Menogon is contraindicated once pregnancy is confirmed, as it has no therapeutic role during an established pregnancy and continued use is not appropriate. It is used specifically to help achieve pregnancy under close specialist monitoring; treatment is stopped once ovulation/pregnancy is confirmed. Assisted-reproduction pregnancies (multiple gestation, in particular) carry a somewhat higher risk of pregnancy complications and congenital anomalies compared with spontaneous conception; patients should discuss this with their treating specialist.

There is no recognized indication for Menogon during breastfeeding. Since it is used only to induce ovulation/pregnancy, it is not relevant to lactating women; consult a physician if fertility treatment is being considered while breastfeeding.

Menogon must be used only under the supervision of a physician experienced in fertility treatment, with monitoring by transvaginal ultrasound and serum estradiol levels throughout treatment. Key precautions include:

• Ovarian Hyperstimulation Syndrome (OHSS): A potentially serious and rarely life-threatening complication marked by rapid ovarian enlargement, abdominal pain/distension, ascites, pleural effusion, electrolyte imbalance, hemoconcentration, and thromboembolic risk. Careful dose titration and monitoring reduce (but do not eliminate) this risk; the lowest effective dose should be used and hCG withheld if excessive ovarian response is seen.
• Multiple pregnancy: Menogon therapy carries a significant risk of multiple gestation (twins or more), which carries additional maternal and perinatal risk.
• Ovarian torsion: Reported in association with gonadotropin therapy and enlarged ovaries.
• Thromboembolism: Reported rarely, particularly in association with severe OHSS.
• Ectopic pregnancy: Women with a history of tubal disease undergoing ART have an increased risk of ectopic pregnancy.
• Pretreatment evaluation should exclude other causes of infertility and confirm normal thyroid, adrenal, and pituitary function where relevant.

Overdosage of Menogon may increase the risk of ovarian hyperstimulation syndrome (OHSS) and multiple follicular development. There is no specific antidote. If overdose is suspected or symptoms such as severe abdominal pain, rapid weight gain, reduced urination, breathlessness, or nausea/vomiting occur, seek immediate medical attention or contact the treating fertility clinic/emergency services promptly; do not attempt to manage suspected OHSS or overdose at home.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children. After reconstitution, use immediately; do not store reconstituted solution for later use unless specifically directed by the product's manufacturer instructions.

Renal/hepatic impairment: Specific dose-adjustment data for Menogon in renal or hepatic impairment are not well established; use with caution and specialist judgment in such patients.

Elderly: Not applicable, as Menogon is used only in reproductive-age men and women for fertility indications.

Pediatric: See Pediatric Uses.

Pregnancy/Lactation: See Pregnancy and Lactation.

Duration of Menogon treatment varies by indication and individual response: ovulation-induction cycles typically last 7–14 days per cycle before an hCG trigger is given; ART/IVF stimulation cycles are similarly around 8–14 days; male hypogonadotropic hypogonadism treatment (with concurrent hCG) is much longer, often several months to over a year, to achieve adequate spermatogenesis. The treating specialist determines when to continue, adjust, or stop therapy based on monitoring results.

Menogon is supplied as a lyophilized powder that must be reconstituted immediately before use with the accompanying diluent (sterile solvent/water for injection), as provided in the pack. Gently swirl (do not shake vigorously) until the powder is fully dissolved into a clear solution. Use the reconstituted solution immediately; discard any unused portion unless the manufacturer's labeling specifically permits short-term storage. Multiple vials may be combined into a single injection volume as directed by the prescribing clinic to reduce the number of injections.

Menotrophin is classified under gonadotropins / fertility agents (human menopausal gonadotropin, hMG).

Menotrophin acts by supplying exogenous FSH and LH bioactivity that bind to FSH and LH receptors on ovarian granulosa/theca cells (in women) or testicular Sertoli/Leydig cells (in men), driving follicular growth and steroidogenesis in women, and supporting spermatogenesis in men (in conjunction with hCG). This replaces or augments the body's own pituitary gonadotropin drive in patients with inadequate endogenous FSH/LH activity.

X

Menogon is not indicated for use in children. It is used only in adults of reproductive age for fertility treatment; safety and efficacy in pediatric populations have not been established and there is no recognized pediatric indication.